Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
نویسندگان
چکیده
منابع مشابه
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of pulmonary arterial hypertension (PAH) was investigated. In this double-blind, placebo-controlled prospective study, 33 patients with PAH started epoprostenol treatment (2 ng.kg(-1)min(-1) starting dose, up to 14+/-2 ng.kg...
متن کاملlower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension
conclusions we observed acceptable results regarding both efficacy and safety with 62.5 mg of bosentan, twice daily in this group of patients. further clinical trials investigating pah with lower dosages of bosentan may be warranted. results no adverse drug reaction was observed during the follow-up. clinical worsening occurred in six (14%) patients, at least one year after treatment, two of th...
متن کاملEndothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Endothelin receptor antagonists are used to treat idiopathic pulmonary arterial hypertension (IPAH), but human pulmonary arterial endothelin receptor expression is not well defined. We hypothesised that disease and treatment would modify normal receptor distribution in pulmonary resistance arteries of children. Using immunohistochemistry and semiquantitative analysis, we investigated endothelin...
متن کاملEpoprostenol Therapy for Pulmonary Arterial Hypertension.
Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the ...
متن کاملAdditional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol.
BACKGROUND Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose epoprostenol (EPO) was evaluated in the present study. METHODS AND RESULTS Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EP...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2004
ISSN: 0903-1936,1399-3003
DOI: 10.1183/09031936.04.00028404